[{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tolebrutininb","moa":"BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Orion Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Orion Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Orion Corporation"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Financing","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ TCGX"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Kreos Capital","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Kreos Capital","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Kreos Capital"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Abivax \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ Undisclosed"},{"orgOrder":0,"company":"Abivax","sponsor":"TCGX","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Obefazimod","moa":"Cap binding complex","graph1":"Immunology","graph2":"Phase III","graph3":"Abivax","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Abivax \/ TCGX","highestDevelopmentStatusID":"10","companyTruncated":"Abivax \/ TCGX"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Cytotoxic Drug","year":"2013","type":"Inapplicable","leadProduct":"Methotrexate","moa":"Dihydrofolate reductase","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"Prednisone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Steroid","year":"2017","type":"Inapplicable","leadProduct":"Triamcinolone","moa":"Glucocorticoid receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Skyepharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Skyepharma","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Skyepharma"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Bpifrance","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Bpifrance"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Symbiosis Pharmaceutical Services","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Series B Financing","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.02,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Symbiosis Pharmaceutical Services","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Symbiosis Pharmaceutical Services"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"INRAE","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ INRAE","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ INRAE"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Clinigen Group","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Licensing Agreement","leadProduct":"MaaT013","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0.029999999999999999,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Clinigen Group","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Clinigen Group"},{"orgOrder":0,"company":"Skyepharma","sponsor":"MaaT Pharma","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2022","type":"Partnership","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"Skyepharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"Skyepharma \/ MaaT Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Skyepharma \/ MaaT Pharma"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"MaaT013","moa":"Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ Undisclosed"},{"orgOrder":0,"company":"MaaT Pharma","sponsor":"EIB","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Protein","year":"2025","type":"Financing","leadProduct":"MaaT013","moa":"||Gut microbiome","graph1":"Immunology","graph2":"Phase III","graph3":"MaaT Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Enema","sponsorNew":"MaaT Pharma \/ EIB","highestDevelopmentStatusID":"10","companyTruncated":"MaaT Pharma \/ EIB"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Opella Healthcare Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Opella Healthcare Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Opella Healthcare Group \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Opella Healthcare Group \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fexofenadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2010","type":"Inapplicable","leadProduct":"SAR153191","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2011","type":"Inapplicable","leadProduct":"SAR153191","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"SAR153191","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"EA Pharma","sponsor":"Kissei Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Carotegrast Methyl","moa":"Alpha-4 integrin||ITGA4\/ITGB1","graph1":"Immunology","graph2":"Phase III","graph3":"EA Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"EA Pharma \/ Kissei Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"EA Pharma \/ Kissei Pharmaceutical"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Belumosudil","moa":"Rho-associated protein kinase 2","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Medsenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Undisclosed"},{"orgOrder":0,"company":"Medsenic","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Arsenic Trioxide","moa":"||Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Undisclosed"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Partnership","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Arsenic Trioxide","moa":"Thioredoxin reductase 1","graph1":"Immunology","graph2":"Phase III","graph3":"Medsenic","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Medsenic \/ Phebra","highestDevelopmentStatusID":"10","companyTruncated":"Medsenic \/ Phebra"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"Toll-like receptor 9","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Massachusetts General Hospital","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"DBV Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"DBV712","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"DBV Technologies","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DBV Technologies \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"DBV Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"FEX60","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Duvakitug","moa":"TNFSF15","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Sanofi \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"FRANCE","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Rilzabrutinib","moa":"Tyrosine-protein kinase BTK","graph1":"Immunology","graph2":"Phase III","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Sanofi \/ Undisclosed"}]

Find Immunology Drugs in Phase III Clinical Development in FRANCE

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Rilzabrutinib

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Rilzabrutinib is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Immunoglobulin G4-Related Disease.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 24, 2025

                          Lead Product(s) : Rilzabrutinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          02

                          Lead Product(s) : Duvakitug

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Teva Pharmaceutical Industries

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Crohn Disease.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          September 22, 2025

                          Lead Product(s) : Duvakitug

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Teva Pharmaceutical Industries

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          03

                          Lead Product(s) : Duvakitug

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Teva Pharmaceutical Industries

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Crohn Disease.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          September 22, 2025

                          Lead Product(s) : Duvakitug

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Teva Pharmaceutical Industries

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          04

                          Lead Product(s) : Duvakitug

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Teva Pharmaceutical Industries

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colitis, Ulcerative.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          September 22, 2025

                          Lead Product(s) : Duvakitug

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Teva Pharmaceutical Industries

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          05

                          Lead Product(s) : Duvakitug

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Teva Pharmaceutical Industries

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Duvakitug is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Colitis, Ulcerative.

                          Product Name : Undisclosed

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          September 22, 2025

                          Lead Product(s) : Duvakitug

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Teva Pharmaceutical Industries

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          06

                          Lead Product(s) : Rilzabrutinib

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Rilzabrutinib is a Other Small Molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Purpura, Thrombocytopenic, Idiopathic.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 06, 2025

                          Lead Product(s) : Rilzabrutinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          07

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Dupixent (dupilumab) is an approved monoclonal antibody works by inhibiting IL-4 and IL-13. It is being investigated for the treatment in 12 years and older with chronic spontaneous urticaria.

                          Product Name : Dupixent

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          November 15, 2024

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          08

                          Lead Product(s) : Rilzabrutinib

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : PRN1008 (rilzabrutinib) is an oral, reversible covalent BTK inhibitor, small molecule drug candidate. It is being evaluated for the treatment of adults with immune thrombocytopenia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 23, 2024

                          Lead Product(s) : Rilzabrutinib

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          09

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Dupixent (dupilumab) is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13), and US FDA has issued a CRL for the sBLA for Dupixent® (dupilumab) in chronic spontaneous urticaria (CSU).

                          Product Name : Dupixent

                          Product Type : Antibody, Unconjugated

                          Upfront Cash : Inapplicable

                          October 20, 2023

                          Lead Product(s) : Dupilumab

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Regeneron Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner

                          10

                          Lead Product(s) : Belumosudil

                          Therapeutic Area : Immunology

                          Study Phase : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Belumosudil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft Rejection.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 13, 2023

                          Lead Product(s) : Belumosudil

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Sanofi Company Banner